DK1512404T3 - Eksterne præparater til behandling af dermatitis - Google Patents

Eksterne præparater til behandling af dermatitis

Info

Publication number
DK1512404T3
DK1512404T3 DK02788607T DK02788607T DK1512404T3 DK 1512404 T3 DK1512404 T3 DK 1512404T3 DK 02788607 T DK02788607 T DK 02788607T DK 02788607 T DK02788607 T DK 02788607T DK 1512404 T3 DK1512404 T3 DK 1512404T3
Authority
DK
Denmark
Prior art keywords
weight
dermatitis
medicine
treatment
cyclodextrin
Prior art date
Application number
DK02788607T
Other languages
Danish (da)
English (en)
Inventor
Hajime Yamada
Akira Yamada
Original Assignee
Cac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cac Corp filed Critical Cac Corp
Application granted granted Critical
Publication of DK1512404T3 publication Critical patent/DK1512404T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02788607T 2002-06-03 2002-11-12 Eksterne præparater til behandling af dermatitis DK1512404T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002161000 2002-06-03
PCT/JP2002/011747 WO2003101460A1 (fr) 2002-06-03 2002-11-12 Preparations a usage externe pour le traitement de la dermatite

Publications (1)

Publication Number Publication Date
DK1512404T3 true DK1512404T3 (da) 2010-01-04

Family

ID=29706567

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02788607T DK1512404T3 (da) 2002-06-03 2002-11-12 Eksterne præparater til behandling af dermatitis

Country Status (14)

Country Link
US (1) US7897161B2 (de)
EP (1) EP1512404B1 (de)
JP (1) JP3820577B2 (de)
KR (1) KR100647857B1 (de)
CN (1) CN1219520C (de)
AT (1) ATE446096T1 (de)
AU (1) AU2002355005B2 (de)
CA (1) CA2488011C (de)
DE (1) DE60234132D1 (de)
DK (1) DK1512404T3 (de)
ES (1) ES2356370T3 (de)
HK (1) HK1060981A1 (de)
TW (1) TWI278318B (de)
WO (1) WO2003101460A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053841A (ja) * 2003-08-05 2005-03-03 Kyouto Biomedical Science:Kk 皮膚外用剤
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
US7919250B2 (en) * 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US7854936B2 (en) 2008-01-14 2010-12-21 Active Organics, Inc. Anti-inflammatory hydrolysate of C. versicolor
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Cac 細胞遊走促進剤及び創傷治療用の経皮吸収剤
ITMI20122002A1 (it) * 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
CA2931862C (en) 2013-11-08 2024-01-23 Carlos Filipe Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions
EP4122469A1 (de) * 2014-03-28 2023-01-25 Paul Maes Zusammensetzung mit cyclodextrin und budesonidderivaten zur behandlung und prophylaxe von pulmonalen entzündungen
AU2015410635B2 (en) * 2015-09-29 2021-08-19 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
KR102071614B1 (ko) 2019-04-30 2020-01-30 김민청 6-디아조-5-옥소-l-노르루신을 포함하는 염증성 피부 질환 치료용 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5799M (de) 1966-03-22 1968-03-25
US3859436A (en) 1968-10-02 1975-01-07 Kolmar Laboratories Sugar composition for topical application
US3777597A (en) 1970-04-29 1973-12-11 Pharmachem Corp Method of shaving employing an aqueous solution of dextran
US5547997A (en) * 1991-10-01 1996-08-20 Chemisches Laboratorium Dr. Kurt Richter Gmbh Plant-derived cosmetic composition and method of treatment of skin
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
FR2719772B1 (fr) * 1994-05-11 1996-08-02 Goemar Lab Sa Composition cosmétique ou pharmaceutique, notamment dermatologique contenant de la laminarine ou des oligosaccharides dérivés de laminarine.
JP2920611B2 (ja) * 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
JPH1025240A (ja) * 1996-04-09 1998-01-27 Dokutaazu Kosumeteikusu:Kk 浴用剤
JPH09315987A (ja) 1996-05-24 1997-12-09 Kureha Chem Ind Co Ltd 泡盛の抗アレルギー有効成分としての利用
DE19710368A1 (de) * 1997-03-13 1998-09-17 Henkel Kgaa Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung
JPH11180813A (ja) * 1997-12-19 1999-07-06 Ichimaru Pharcos Co Ltd 海藻抽出物含有抗菌・防腐剤
AU3657100A (en) * 1999-03-12 2000-10-04 Biotec Asa Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents
US20030130248A1 (en) * 2000-05-31 2003-07-10 Mozzone Keith C. Topical anti-inflammatory compositions
JP2002114670A (ja) 2000-10-02 2002-04-16 Noevir Co Ltd 抗菌性皮膚外用剤
JP2002060314A (ja) 2001-09-18 2002-02-26 Hakuto Co Ltd 皮膚外用剤

Also Published As

Publication number Publication date
US7897161B2 (en) 2011-03-01
EP1512404B1 (de) 2009-10-21
AU2002355005B2 (en) 2006-04-13
HK1060981A1 (en) 2004-09-03
KR100647857B1 (ko) 2006-11-23
EP1512404A4 (de) 2006-04-12
US20050175640A1 (en) 2005-08-11
DE60234132D1 (de) 2009-12-03
CA2488011C (en) 2008-02-12
JP3820577B2 (ja) 2006-09-13
CA2488011A1 (en) 2003-12-11
CN1219520C (zh) 2005-09-21
KR20050016479A (ko) 2005-02-21
AU2002355005A1 (en) 2003-12-19
WO2003101460A1 (fr) 2003-12-11
TW200307552A (en) 2003-12-16
ES2356370T3 (es) 2011-04-07
CN1466952A (zh) 2004-01-14
JPWO2003101460A1 (ja) 2005-09-29
TWI278318B (en) 2007-04-11
ATE446096T1 (de) 2009-11-15
EP1512404A1 (de) 2005-03-09

Similar Documents

Publication Publication Date Title
DK1512404T3 (da) Eksterne præparater til behandling af dermatitis
NO20054988L (no) Preparater og metoder for behandling av cancer
NO20052399D0 (no) Taksaner som er kovalent bundet til hyaluronsyre eller hyaluronsyrederivater.
NO20051575L (no) Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet
BRPI0617412B8 (pt) anticorpo antiglipicano-3, agente anticâncer compreendendo o mesmo, bem como seu uso e seu processo de produção
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
WO2004093722A3 (en) Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
IT1282994B1 (it) Derivati del polisaccaride k5 aventi elevata attivita' anticoagulante
DK1366082T3 (da) Höjsulfaterede derivater af K5-polysaccharid og deres fremstilling
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
KR0181763B1 (ko) 피부염의 치료외용제
Bakker et al. Evaluation of 7.5 years of surviving sepsis campaign guidelines
DE60334617D1 (de) Epimerderivate von k5-polysaccharid mit hohem sulfatierungsgrad
NO20081415L (no) Fremgangsmate for utforelse av en perkutan koronar intervensjon
DE602004006768D1 (de) Aus mit gamma-strahlen bestrahltem pektin hergestellte pektinfilme
Kerimoglu et al. The effects of dabigatran etexilate on fracture healing in rats: an experimental study
Poposka et al. P1495ECG parameters as predictors of response to cardiac resynchronization therapy
Ikwueze et al. A review of current and future prospects in cancer prevention and chemotherapy
ATE282404T1 (de) Verwendung von biguanid und pyrimidin-derivaten zur herstellung topischer hautpflegezubereitungen
Gaballah et al. Catheter-directed and mechanical thrombolysis for management of lower extremity iliofemoral deep venous thrombosis: a single pediatric institutional experience
UA118187U (uk) Спосіб лікування хелікобактер-асоційованого гастродуоденіту у поєднанні з атопічним дерматитом у дітей
Puymirat et al. 009: Comparison of bleeding complications and three-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction. The FAST-MI registry
WO2003013498A3 (de) Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen
HARSAN et al. The Effect of Dimethyltin Phenylarsonate PhAsO3SnMe2 on the Roots, Shoots and Rhizogenesys of Chrysanthemum in Vitro
NO20071452L (no) TNF-bindende protein-1 i behandling av psoriasis.